



Editorial Commentary

Metastases free thyroid cancer patients harbouring *TERT* mutations may benefit from a more intensive treatment and follow-up

Alessandro Antonelli¹, Silvia Martina Ferrari¹, Giusy Elia¹, Armando Patrizio¹, Poupak Fallahi²

¹Department of Clinical and Experimental Medicine, ²Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy

Correspondence to: Alessandro Antonelli, MD. Director, Immuno-Endocrine Section of Internal Medicine; Professor of Medicine, Endocrinology, Clinical Pathology; Head, Laboratory of Primary Human Cells; Department of Clinical and Experimental Medicine, University of Pisa, School of Medicine, Via Savi, 10, I-56126, Pisa, Italy. Email: alessandro.antonelli@med.unipi.it.

Provenance: This is an invited article commissioned by the Section Editor De-Tao Yin (Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China).

Comment on: Bornaoud C, Descotes F, Decaussin-Petrucci M, *et al.* *TERT* promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. *Eur J Cancer* 2019;108:41-9.

Submitted May 10, 2019. Accepted for publication May 14, 2019.

doi: 10.21037/gs.2019.05.05

View this article at: <http://dx.doi.org/10.21037/gs.2019.05.05>

The telomerase reverse transcriptase (*TERT*) was discovered in the beginning of 1980s. This enzyme is able to preserve the chromosomes integrity by adding to their ends a specific nucleotide sequences called “telomeres” (1,2). To date, it is also well established that *TERT* plays a crucial role in the immortalization and proliferation of malignant cells in several type of cancers, thyroid cancer (TC) included (3,4). The most common *TERT* mutations identified among TC are *C288T* and *C250T*. A recent review has shown that 10% of evaluated TC, of different types, harboured *TERT* mutations: 86.1%, *C288T*; 12%, *C250T*; 2.1% other types. The prevalence was higher among the most aggressive subtypes of TC with the highest value in the anaplastic TC (56.8%). In fact a significant association has been reported between *TERT* mutations and: older age, larger tumor size, extrathyroidal invasion, lymph node or distant metastases, TNM stage, or recurrence. *TERT* promoter mutations might also be present in *BRAF V600E* positive TC. Patients affected by tumors with these two combined mutations have poorer prognosis and outcomes (5). These data are supported by a meta-analysis, which showed that papillary thyroid cancers (PTCs) harbouring both *BRAF* and *TERT* promoter mutations, are more aggressive than those with *BRAF*, or *TERT* promoter mutations, alone. By specifying the *BRAF* and *TERT* promoter mutations status, PTCs can

be classified into four distinct risk groups with decreasing aggressiveness as follows: *BRAF* and *TERT* mutations, *TERT* mutation only, *BRAF* mutation only, or absence of both (6).

Through the cellular samples obtained by fine needle aspiration (FNA) of thyroid nodules, it is possible to define the molecular profile of the sampled thyroid nodules, improving their diagnosis and management. *BRAF V600E* is the most studied and experienced mutation of cancer for thyroid nodule due to its high specificity. The diagnostic yield can be augmented testing FNA samples for more mutations associated with TC such as *TERT*, *BRAF*, *PAX8/PPARγ*, *RAS*, and *RET/PTC*: thyroid nodules found with any of these mutations have a higher chance to be malignant. Thus the molecular profiling of thyroid nodules, especially if with indeterminate cytology at the FNA, is a helpful tool for their clinical management (7,8).

Bornaoud *et al.* (9) studied the prognostic value of *TERT* promoter mutations in TC. They enrolled in a prospective study [2010–2013], 173 patients affected by differentiated TC [pT3 >20 mm, pT4 or M1; 2004 World Health Organization]. All patients were treated with total (or near total) thyroidectomy, plus lymph node dissection, (when indicated) and radioiodine (RAI) therapy. Follow-up and therapies adhered to American

Thyroid Association (ATA) guidelines [2009] (10,11). The subjects were restaged according to system defined by Tuttle *et al.* (12), and the new ATA guidelines [2016] (13). Patients were considered: (I) in remission when classified as excellent, or indeterminate response, after the first treatment; (II) whereas as having persistent disease, in those having biochemical, or structural incomplete response. Subsequently, once a year, thyroglobulin (Tg), and cervical ultrasonography (and when appropriate also other imaging), were obtained to update the oncological status of patients, up to 5 years. The patients were classified as having: (I) no evidence of disease (NED) (Tg <1 mg/L, negative AbTg, no structural evidence of TC) (13); (II) recurrent disease (biological; morphological; local; or metastatic). Deaths due or not to cancer, were registered. Mutations of *TERT* promoter, of *BRAF* exon 15, *HRAS* exon 3, *NRAS* exon 3 were evaluated in all tumors. *TERT* promoter mutations were present in 20.2% TC (the prevalence was higher in tumors with histological aggressive features, than in non-aggressive: 32.7%, *vs.* 15.3%, respectively). *TERT* mutations were also more frequently reported among patients older than 45 years, pT4 stage cancers, metastatic, or with extrathyroidal invasion. A poor prognosis was associated with *TERT* mutations in all the patients ($P < 0.001$), but not in non-metastatic. In particular, in non-metastatic patients event-free survival was related with age ≥ 45 , histological aggressive features and vascular invasion.

BRAF mutation was detected in 50 tumors (28.9%) with no significant difference between aggressive (24.5%) and non-aggressive tumors (30.6%), whereas *RAS* mutation was found in 27 TC (15.6%) (*NRAS*, 17; *HRAS*, 10). The association of *TERT* and *BRAF* was found in 7.5% TC, and of *RAS* and *TERT* 5.2%. Event-free survival was not related with these mutations in all patients. In multi-variate analysis, histological aggressive characteristics were linked to worse event-free survival. *TERT* mutations were strongly associated with a poorer prognosis in subjects with no metastases and aggressive histological features (9); but not *BRAF*, or *RAS*.

BRAF V600E has been associated, by several data, with aggressive behavior of PTC: recurrence; RAI refractory TC; extrathyroidal extension; and lymph node metastases (14,15). PTC-specific mortality was associated with *BRAF V600E* in a study on 1,849 patients (16). These and other studies suggested an important tumorigenic role of *BRAF V600E* in the aggressiveness, or progression, of PTC. However, other studies were also reported that did not find any association with features of TC aggressiveness (4,17,18).

Most of previous studies assessed the impact of *TERT*, on long-term outcomes, finding an association with high death risk, or of RAI courses (19,20). On the other hand, the Bournaud's study had evaluated the patient status every year, during the follow-up (9). With their study, Bournaud *et al.* showed that *TERT* mutations were related with incomplete response (after the initial therapy), and a lower NED after 5 years, even in initially non-metastatic patients, supporting a closer monitoring and more aggressive treatment of these patients (9). According to these data, few years ago, Xu *et al.* reported a retrospective study of patients with PTC, with initial low-risk histological features, and *TERT* mutations, subsequently developing metastatic disease (21).

In conclusion, *TERT* mutations may do not have a better prognostic value than histology, but they have been linked to a worse prognosis in metastasis-free patients without aggressive histological characteristics. For this reason patients affected by TC harbouring *TERT* mutations may benefit from a more intensive follow-up, and treatment. More studies in larger number of TC patients are needed to confirm the results of the Bournaud's paper, but its research could represent a promising advancement in identifying metastasis free TC patients deserving a more intensive follow-up, and treatment (9).

Acknowledgments

None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Greider CW, Blackburn EH. Identification of a specific telomere terminal transferase activity in Tetrahymena extracts. *Cell* 1985;43:405-13.
2. Szostak JW, Blackburn EH. Cloning yeast telomeres on linear plasmid vectors. *Cell* 1982;29:245-55.
3. Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. *Trends Biochem Sci* 2013;38:426-34.
4. Xing M. Genetic-guided Risk Assessment and Management of Thyroid Cancer. *Endocrinol Metab Clin North Am* 2019;48:109-24.
5. Jin A, Xu J, Wang Y. The role of *TERT* promoter

- mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer. *Medicine (Baltimore)* 2018;97:e11548.
6. Vuong HG, Ahmed AMA, Duong UNP, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. *Clin Endocrinol (Oxf)* 2017;87:411-7.
 7. Ferrari SM, Fallahi P, Ruffilli I, et al. Molecular testing in the diagnosis of differentiated thyroid carcinomas. *Gland Surg* 2018;7:S19-29.
 8. Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antidiabetics in primary human anaplastic thyroid cancer cells. *Clin Endocrinol (Oxf)* 2009;70:946-53.
 9. Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. *Eur J Cancer* 2019;108:41-9.
 10. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009;19:1167-214.
 11. Antonelli A, Miccoli P, Fallahi P, et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. *Thyroid* 2003;13:479-84.
 12. Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. *Thyroid* 2010;20:1341-9.
 13. Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 2016;26:1-133.
 14. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. *J Clin Endocrinol Metab* 2005;90:6373-9.
 15. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. *J Clin Oncol* 2015;33:42-50.
 16. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. *JAMA* 2013;309:1493-501.
 17. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. *Endocr Rev* 2007;28:742-62.
 18. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. *Clin Endocrinol (Oxf)* 2006;65:364-8.
 19. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. *J Clin Endocrinol Metab* 2014;99:E754-65.
 20. Kim TH, Ki CS, Kim HS, et al. Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations. *J Clin Endocrinol Metab* 2017;102:1757-64.
 21. Xu B, Tuttle RM, Sabra MM, et al. Primary thyroid carcinoma with low-risk histology and distant metastases: clinicopathologic and molecular characteristics. *Thyroid* 2017;27:632-40.

Cite this article as: Antonelli A, Ferrari SM, Elia G, Patrizio A, Fallahi P. Metastases free thyroid cancer patients harbouring *TERT* mutations may benefit from a more intensive treatment and follow-up. *Gland Surg* 2019;8(3):298-300. doi: 10.21037/gs.2019.05.05